August 04, 2011 08:39 ET

Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Generic Drug Makers Enjoy Strong North American Sales

NEW YORK, NY--(Marketwire - Aug 4, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drugs - Generic industry and are offering free analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at to have free access to these research reports.

The generic drug industry saw increased acquisition and expansion activity in 2010 and early 2011. The upside to those moves is starting to be seen as many companies post their second quarter results. Get your free reports on Mylan Inc. and Watson Pharmaceuticals Inc. at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Mylan Inc. and Watson Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Mylan Inc. saw its second quarter profits nearly triple as expansion related costs lessened. The gains were led by strong sales in North America which climbed 27% to $749.1 million. The launch of several new generic drugs was behind the improved sales. Mylan Inc. report is accessible for free by registering today at

Watson Pharmaceuticals Inc. could also benefit from recent drug launches. Watson Laboratories Inc., a subsidiary of WPI, recently began shipping Amethia, a generic version of Duramed Pharmaceuitcals' Seasonique. The branded drug saw strong sales in 2010 and its generic counterpart should do the same for WPI. Watson Pharmaceuticals Inc. report is accessible for free by registering today at

Overall, the generic drug industry is enjoying strong sales to North America. Companies now shedding acquisition related expenses are seeing some of the biggest gains. Maintaining a steady pipeline of products to market is still pivotal and investors may want to track companies with the most recent drug launches.

The two Drugs - Generic stocks research reports are available for free by signing up now on


Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information